Patients aged ≥ 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy [2] (multiple letters)

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1583-1584

  Balducci, L ^a   Lyman, G H ^a   Ozer, H ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; MITOXANTRONE; PIRARUBICIN; PREDNIMUSTINE; PREDNISONE; VINBLASTINE; VINCRISTINE; CHOP PROTOCOL; DOXORUBICIN;

AGED; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RATE; LARGE CELL LYMPHOMA; LETTER; LYMPHOMA; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; AGE; NOTE; RISK FACTOR;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFECTION; NEUTROPENIA; PRACTICE GUIDELINES; PREDNISONE; RISK FACTORS; VINCRISTINE;

EID: 0035281526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2001.19.5.1583     Document Type: Letter

References (0)